Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
نویسندگان
چکیده
Non-Hodgkin lymphoma can occur concurrently with chronic phase-chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second-generation tyrosine kinase inhibitors and rituximab-CHOP for patients newly diagnosed with CML and non-Hodgkin lymphoma is effective for both diseases. However, we found that this treatment combination may induce severe myelosuppression.
منابع مشابه
Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among ...
متن کاملCoexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملCombination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
BACKGROUND Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown single-drug activity in relapsed or refractory B-cell malignancies. We investigated the safety and efficacy of ibrutinib in combination ...
متن کاملConcomitant Secondary Peripheral T-cell Lymphoma with Therapy-related Chronic Myelomonocytic Leukemia in a Patient with History of High-grade Follicular Lymphoma
A secondary myeloid or lymphoid neoplasm is not infrequently associated with a primary tumor, solid or hematopoietic, post cytotoxic treatment or radiation. Concurrent secondary neoplasms derived from distinct myeloid and lymphoid cell origins are rare. It is not only a diagnostic challenge, but makes for difficult treatment management. We report a very rare occurrence in 63-year-old male with ...
متن کاملIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
Idelalisib is a first-in-class, oral, selective phosphatidylinositol 3-kinase δ inhibitor that offers a chemotherapy-free option for patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Clinical trials in iNHL have evaluated idelalisib as monotherapy and as combination therapy with rituximab, bendamustine, and rituximab + bendamustine. When administered to heavily pr...
متن کامل